GRANULOMA REGULATION THROUGH SOMATOSTATIN RECEPTOR SSTR2

通过生长抑素受体 SSTR2 调节肉芽肿

基本信息

  • 批准号:
    2443766
  • 负责人:
  • 金额:
    $ 8.96万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1996
  • 资助国家:
    美国
  • 起止时间:
    1996-07-01 至 2001-06-30
  • 项目状态:
    已结题

项目摘要

Granulomatous inflammation is characteristic of many diseases like Crohn's disease, sarcoidosis and primary biliary cirrhosis. Granulomas are focal collections of inflammatory cells, tightly regulated by T cells. In turn, other inflammatory cells types regulate granuloma T cells. Diseases like IBD develop when there is disruption of this cross regulatory circuitry. Much of this regulatory circuitry proceeds through release of neurokines and other lymphokines. Somatostatin (SOM) is one such neurokine that alters lymphocyte responses. Granuloma macrophages secrete SOM. Murine granuloma T cells display SOM receptors as do cells in human granulomas. Five distinct SOM receptors (SSTR) are cloned, sequenced, and characterized. Our current evidence indicates that SSTR2 is the only SOM receptor expressed on granuloma T cells. In addition, granuloma cells express both isoforms of SSTR2. SOM inhibits interferon- gamma (IFN-gamma) release from granuloma T cells. SOM may prove to be an important regulator of chronic inflammation, since IFN-gamma is a pivotal cytokine that regulates many inflammatory cell types. Therefore, to further elucidate the importance of SSTR2 in inflammation, this project will pursue these four hypotheses: 1.) SOM regulates IFN-gamma release from granuloma T cells through interaction with SSTR2, 2.) SSTR2 expression is regulated by T cell activation, 3) The two isoforms of SSTR2 differ in ability to inhibit IFN-gamma release, 4) SOM controls granulomatous responses in vivo by interaction with SSTR2. Murine schistosomiasis provides a well defined natural model system to study granulomas in the intestines and liver. Granulomas in murine schistosomiasis express SOM, SSTR2 and other aspects of the SOM circuit. Thus, we will use cells isolated from these granulomas to achieve the following aims: Aim 1: Determine if SOM interacts directly with T cell SSTR2 to regulate IFN-gamma release without the interposed participation of another cell type using receptor blocking antibody, specific agonists, flow cytometry and cloned T cells with abrogated SSTR2 display. Aim 2: Determine if T cell activation affects SSTR2 mRNA and protein synthesis, and SSTR2 phosphorylation, and using quantitative RT-PCR, nuclear run-off analysis, flow cytometry, western blotting and immunoprecipitation. Aim 3: Determine if the two isoforms of SSTR2 are differentially regulated and have different capacity to inhibit T cell IFN-gamma release using isoform specific quantitative RT-PCR and immunoprecipitation, and selective transfection of the isoforms. Aim 4: Determine if intralesional SOM interacts with SSTR2 to regulate granulomas in vivo using SSTR2 blocking antibodies and transgenic mice with selectively impaired T cell SSTR2 display. Our hope is that these discoveries will lead to new therapies for IBD.
肉芽肿性炎症是许多疾病的特征

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID E ELLIOTT其他文献

DAVID E ELLIOTT的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID E ELLIOTT', 18)}}的其他基金

Modulation of Th17 plasticity by intestinal paleobiomic fauna
肠道古生物群对 Th17 可塑性的调节
  • 批准号:
    10012257
  • 财政年份:
    2014
  • 资助金额:
    $ 8.96万
  • 项目类别:
Modulation of Th17 plasticity by intestinal paleobiomic fauna
肠道古生物群对 Th17 可塑性的调节
  • 批准号:
    10477220
  • 财政年份:
    2014
  • 资助金额:
    $ 8.96万
  • 项目类别:
Modulation of Th17 plasticity by intestinal paleobiomic fauna
肠道古生物群对 Th17 可塑性的调节
  • 批准号:
    10162301
  • 财政年份:
    2014
  • 资助金额:
    $ 8.96万
  • 项目类别:
Regulation of Inflammation by Somatostatin via SSTR 2
生长抑素通过 SSTR 2 调节炎症
  • 批准号:
    6651104
  • 财政年份:
    2002
  • 资助金额:
    $ 8.96万
  • 项目类别:
Regulation of Inflammation by Somatostatin via SSTR 2
生长抑素通过 SSTR 2 调节炎症
  • 批准号:
    6546970
  • 财政年份:
    2002
  • 资助金额:
    $ 8.96万
  • 项目类别:
Regulation of Inflammation by Somatostatin via SSTR 2
生长抑素通过 SSTR 2 调节炎症
  • 批准号:
    6795585
  • 财政年份:
    2002
  • 资助金额:
    $ 8.96万
  • 项目类别:
Regulation of Inflammation by Somatostatin via SSTR 2
生长抑素通过 SSTR 2 调节炎症
  • 批准号:
    7089897
  • 财政年份:
    2002
  • 资助金额:
    $ 8.96万
  • 项目类别:
Regulation of Inflammation by Somatostatin via SSTR 2
生长抑素通过 SSTR 2 调节炎症
  • 批准号:
    6909892
  • 财政年份:
    2002
  • 资助金额:
    $ 8.96万
  • 项目类别:
GRANULOMA REGULATION THROUGH SOMATOSTATIN RECEPTOR SSTR2
通过生长抑素受体 SSTR2 调节肉芽肿
  • 批准号:
    2904947
  • 财政年份:
    1996
  • 资助金额:
    $ 8.96万
  • 项目类别:
GRANULOMA REGULATION THROUGH SOMATOSTATIN RECEPTOR SSTR2
通过生长抑素受体 SSTR2 调节肉芽肿
  • 批准号:
    2134373
  • 财政年份:
    1996
  • 资助金额:
    $ 8.96万
  • 项目类别:

相似海外基金

Modulation of T lymphocyte Activation by ß2-Adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    RGPIN-2019-06980
  • 财政年份:
    2022
  • 资助金额:
    $ 8.96万
  • 项目类别:
    Discovery Grants Program - Individual
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
  • 批准号:
    10581488
  • 财政年份:
    2022
  • 资助金额:
    $ 8.96万
  • 项目类别:
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574979-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 8.96万
  • 项目类别:
    University Undergraduate Student Research Awards
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
  • 批准号:
    10332251
  • 财政年份:
    2022
  • 资助金额:
    $ 8.96万
  • 项目类别:
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574984-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 8.96万
  • 项目类别:
    University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574985-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 8.96万
  • 项目类别:
    University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574978-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 8.96万
  • 项目类别:
    University Undergraduate Student Research Awards
Investigating the cell-based activity of a new class of cytotoxic T-lymphocyte antigen-4 (CTLA-4) small molecule inhibitors
研究一类新型细胞毒性 T 淋巴细胞抗原 4 (CTLA-4) 小分子抑制剂的细胞活性
  • 批准号:
    444149
  • 财政年份:
    2021
  • 资助金额:
    $ 8.96万
  • 项目类别:
    Operating Grants
Novel pathways in T lymphocyte differentiation and function
T 淋巴细胞分化和功能的新途径
  • 批准号:
    RGPIN-2015-05491
  • 财政年份:
    2021
  • 资助金额:
    $ 8.96万
  • 项目类别:
    Discovery Grants Program - Individual
Modulation of T lymphocyte Activation by ß2-Adrenergic Receptor Signalling Pathways
通过 α2-肾上腺素能受体信号通路调节 T 淋巴细胞激活
  • 批准号:
    RGPIN-2019-06980
  • 财政年份:
    2021
  • 资助金额:
    $ 8.96万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了